V Square Quantitative Management LLC Increases Holdings in Bristol-Myers Squibb (NYSE:BMY)

V Square Quantitative Management LLC raised its position in shares of Bristol-Myers Squibb (NYSE:BMY) by 3.8% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 43,632 shares of the biopharmaceutical company’s stock after acquiring an additional 1,580 shares during the quarter. V Square Quantitative Management LLC’s holdings in Bristol-Myers Squibb were worth $2,258,000 at the end of the most recent quarter.

Several other large investors have also bought and sold shares of BMY. Fisher Asset Management LLC boosted its position in Bristol-Myers Squibb by 129.6% during the 4th quarter. Fisher Asset Management LLC now owns 223,431 shares of the biopharmaceutical company’s stock valued at $11,464,000 after acquiring an additional 126,122 shares in the last quarter. NBC Securities Inc. boosted its position in shares of Bristol-Myers Squibb by 26.5% in the 1st quarter. NBC Securities Inc. now owns 15,118 shares of the biopharmaceutical company’s stock worth $819,000 after purchasing an additional 3,169 shares in the last quarter. Massmutual Trust Co. FSB ADV boosted its position in shares of Bristol-Myers Squibb by 4.0% in the 1st quarter. Massmutual Trust Co. FSB ADV now owns 6,221 shares of the biopharmaceutical company’s stock worth $337,000 after purchasing an additional 240 shares in the last quarter. Perpetual Ltd boosted its position in shares of Bristol-Myers Squibb by 63.6% in the 1st quarter. Perpetual Ltd now owns 31,566 shares of the biopharmaceutical company’s stock worth $1,712,000 after purchasing an additional 12,266 shares in the last quarter. Finally, KMG Fiduciary Partners LLC boosted its position in shares of Bristol-Myers Squibb by 4.1% in the 1st quarter. KMG Fiduciary Partners LLC now owns 27,504 shares of the biopharmaceutical company’s stock worth $1,492,000 after purchasing an additional 1,092 shares in the last quarter. 76.41% of the stock is owned by institutional investors.

Bristol-Myers Squibb Stock Performance

Shares of NYSE:BMY traded down $0.62 during midday trading on Friday, hitting $52.56. The company had a trading volume of 1,090,130 shares, compared to its average volume of 14,722,139. The company has a debt-to-equity ratio of 2.86, a current ratio of 1.16 and a quick ratio of 1.02. The company has a market cap of $106.54 billion, a price-to-earnings ratio of -17.15, a PEG ratio of 13.75 and a beta of 0.46. Bristol-Myers Squibb has a 12-month low of $39.35 and a 12-month high of $57.09. The company has a fifty day moving average of $50.23 and a two-hundred day moving average of $46.41.

Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings results on Friday, July 26th. The biopharmaceutical company reported $2.07 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.64 by $0.43. Bristol-Myers Squibb had a positive return on equity of 12.51% and a negative net margin of 14.06%. The business had revenue of $12.20 billion during the quarter, compared to analyst estimates of $11.54 billion. During the same quarter in the prior year, the business posted $1.75 EPS. Bristol-Myers Squibb’s revenue for the quarter was up 8.7% compared to the same quarter last year. On average, equities research analysts expect that Bristol-Myers Squibb will post 0.77 EPS for the current fiscal year.

Bristol-Myers Squibb Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, November 1st. Shareholders of record on Friday, October 4th will be paid a $0.60 dividend. The ex-dividend date is Friday, October 4th. This represents a $2.40 dividend on an annualized basis and a yield of 4.57%. Bristol-Myers Squibb’s payout ratio is presently -77.42%.

Analyst Upgrades and Downgrades

BMY has been the topic of a number of analyst reports. TD Cowen boosted their price target on Bristol-Myers Squibb from $53.00 to $59.00 and gave the stock a “hold” rating in a research report on Monday, October 7th. Deutsche Bank Aktiengesellschaft dropped their price target on Bristol-Myers Squibb from $53.00 to $45.00 and set a “hold” rating on the stock in a research report on Tuesday, July 23rd. BMO Capital Markets reaffirmed a “market perform” rating and issued a $48.00 price objective on shares of Bristol-Myers Squibb in a research report on Monday, September 23rd. Barclays upped their price objective on Bristol-Myers Squibb from $42.00 to $43.00 and gave the company an “underweight” rating in a research report on Monday, October 7th. Finally, StockNews.com upgraded shares of Bristol-Myers Squibb from a “buy” rating to a “strong-buy” rating in a research note on Monday, July 29th. Two investment analysts have rated the stock with a sell rating, fourteen have issued a hold rating, one has issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $53.20.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.